Insight into human allogeneic CAR-T therapy: an open-access dataset

Area of Science:

• Immunotherapy
• Oncology
• Pharmacometrics

Background:

• Chimeric antigen receptor T-cell (CAR-T) therapy is effective for various cancers, often used after other treatments.
• Allogeneic CAR-T products offer advantages over autologous options, including better cell quality and cost-effectiveness.
• Mathematical modeling is crucial for understanding CAR-T cell exposure-response relationships due to their unique nature.

Purpose of the Study:

• To address the challenge of limited and fragmented clinical data for CAR-T cell therapy.
• To create a comprehensive dataset of human clinical trials involving allogeneic CAR-T cells for hematological disorders.
• To facilitate robust parametrization of mathematical models for allogeneic CAR-T cell therapy.

Main Methods:

• Aggregation of human clinical trial data.
• Focus on trials utilizing allogeneic CAR-T cells.
• Data compilation for hematological disorders.

Main Results:

• A comprehensive dataset of allogeneic CAR-T cell clinical trials has been established.
• The dataset facilitates improved data availability and quality for modeling purposes.
• This resource supports the development of more accurate exposure-response models.

Conclusions:

• The curated dataset is essential for advancing the mathematical modeling of allogeneic CAR-T cell therapy.
• Improved models can lead to a better understanding of CAR-T cell efficacy and safety.
• This work supports the optimization of allogeneic CAR-T cell treatments for hematological malignancies.